HR1 Cell Line

HR1 cells are HEK 293 cells stably expressing conditional kinase <U+2206>Raf-1:ER* from the pCMV Neo Myc plasmid. <U+2206>Raf-1:ER* (also known as <U+2206>CRAF:ER*) consists of the isolated kinase domain of c-Raf1 fused in-frame to a modified form of the hormone binding domain of the estrogen receptor (hbER*) that can be de-repressed by 4-hydroxytamoxifen (4-HT) but not ?-estradiol. In this case the * refers to a point mutation that ablates estradiol binding but allows 4-HT binding.

Contributors

Inventor Institute
Simon Cook Babraham Institute
Cat. #: 153329
Tool sub type: Continuous
Unit size: 1×10^6 cells / vial
Research Fields: Apoptosis and autophagy;Cancer;Cell biology;Cell signaling and signal transduction;Immunology
Organism: Human
Tissue: Kidney
Growth properties: Adherent cell line
Alternate name: RAF proto-oncogene serine/threonine-protein kinase (EC:2.7.11.1), Proto-oncogene c-RAF, cRaf, Raf-1
Product description: HR1 cells are HEK 293 cells stably expressing conditional kinase ∆Raf-1:ER* from the pCMV Neo Myc plasmid. ∆Raf-1:ER* (also known as ∆CRAF:ER*) consists of the isolated kinase domain of c-Raf1 fused in-frame to a modified form of the hormone binding domain of the estrogen receptor (hbER*) that can be de-repressed by 4-hydroxytamoxifen (4-HT) but not β-estradiol. In this case the * refers to a point mutation that ablates estradiol binding but allows 4-HT binding. Activation of ∆Raf-1:ER* leads to the selective activation of the ERK1/2 pathway. This cell line can be used to study the cellular role and factors impacting on the ERK1/2 signalling pathway such as gene expression, cell proliferation, cell cycle arrest and cell death. The cells are G418 resistant. Conditional kinase activation of ∆Raf-1:ER* can be induced with 100nM 4-HT.
Conditional: Yes
Conditional description: Stable transfectant, conditional functionality: c-Raf1 kinase activity and ERK1/2 signalling pathway activated following 4-hydroxytamoxifen (4-HT) treatment of cells.
Production details: HEK 293 cells were transfected with the pCMV Neo Myc plasmid expressing â?‚ˆ?‚†Raf-1:ER*. Stable transfectants were selected by neomycin resistance using G418 (Geneticin) and ring cloning.
Cellosaurus ID: CVCL_2676
Parental cell line: HEK 293
Disease: Cancer
Format: Frozen
Shipping conditions: Dry ice
Growth medium: Phenol red-free Dulbecco's modified Eagle's medium (DMEM) high glucose version, 2 mM L-glutamine, 10% fetal bovine serum (FBS), 400 ?g/ml G418 (Geneticin).
References:

Gilley et al. 2009. Cell Signal. 21(6):969-77. PMID: 19249353.

ERK1/2, but not ERK5, is necessary and sufficient for phosphorylation and activation of c-Fos.

Wiggins et al. 2007. Cell Signal. 19(12):2605-11. PMID: 17884340.

c-Cbl is not required for ERK1/2-dependent degradation of BimEL.

Ewings et al. 2007. EMBO J. 26(12):2856-67. PMID: 17525735.

ERK1/2-dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl-1 and Bcl-xL.

Boughan et al. 2006. J Biol Chem. 281(1…

Related Tools for Cell lines

Cat. # Tool Name
151447 CMT 64 Cell Line Key Info View Tool
151463 Omega-E Packaging Cell Line Key Info View Tool
151488 B6.1.1 Mouse ES Cell Line Key Info View Tool
151663 MEF PKCe KO KI Cell Line Key Info View Tool
151449 JIM1 Cell Line Key Info View Tool

Related News

UM-UC-10 Cell Line. Image courtesy of the European Collection of Authenticated Cell Cultures (ECACC), UK.
Cell Lines

Popular cell lines now available only from CancerTools.org

Read More
Cell Lines

New cell lines: murine melanocyte and melanoblast cell lines from Dr. Elena Sviderskaya

Read More
Image Reference: 2x PTEN -/- mouse prostate cancer cell lines (MuCap system). Histology staining of syngraft tumours (Van Duijn et al., 2018).
Cell Lines

38 new prostate cancer cell lines

Read More

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.